These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 3861121)

  • 1. Electrophysiological studies of the role of cholecystokinin in the substantia nigra and its interactions with dopamine.
    Skirboll LR; Hommer DW
    Ann N Y Acad Sci; 1985; 448():275-82. PubMed ID: 3861121
    [No Abstract]   [Full Text] [Related]  

  • 2. Peptide-monoamine coexistence: studies of the actions of cholecystokinin-like peptide on the electrical activity of midbrain dopamine neurons.
    Skirboll LR; Grace AA; Hommer DW; Rehfeld J; Goldstein M; Hökfelt T; Bunney BS
    Neuroscience; 1981; 6(11):2111-24. PubMed ID: 6120481
    [No Abstract]   [Full Text] [Related]  

  • 3. Comparison between the pharmacology of dopamine receptors mediating the inhibition of cell firing in rat brain slices through the substantia nigra pars compacta and ventral tegmental area.
    Bowery B; Rothwell LA; Seabrook GR
    Br J Pharmacol; 1994 Jul; 112(3):873-80. PubMed ID: 7921615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of ethanolamine-O-sulphate injection into the rat substantia nigra: electrophysiological studies.
    Oakley NR; Dray A
    Brain Res; 1978 Sep; 153(2):387-91. PubMed ID: 210885
    [No Abstract]   [Full Text] [Related]  

  • 5. Interactions of cholecystokinin and dopamine in the nucleus accumbens.
    Wang RY; White FJ; Voigt MM
    Ann N Y Acad Sci; 1985; 448():352-60. PubMed ID: 2862829
    [No Abstract]   [Full Text] [Related]  

  • 6. Apomorphine-induced inhibition of striatal dopamine release: role of dopaminergic receptors in substantia nigra.
    Maggi A; Bruno F; Cattabeni F; Groppetti A; Parenti M; Racagni G
    Brain Res; 1978 Apr; 145(1):180-4. PubMed ID: 205324
    [No Abstract]   [Full Text] [Related]  

  • 7. Effects of D1 and D2 dopamine receptor stimulation on the activity of substantia nigra pars reticulata neurons in 6-hydroxydopamine lesioned rats: D1/D2 coactivation induces potentiated responses.
    Weick BG; Walters JR
    Brain Res; 1987 Mar; 405(2):234-46. PubMed ID: 2952219
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Function of nigral dopamine receptors?
    Glick SD; Crane LA
    Brain Res; 1978 Nov; 156(2):380-1. PubMed ID: 568507
    [No Abstract]   [Full Text] [Related]  

  • 9. Correlation between locomotor stimulation and the electrophysiological effects of low doses of morphine on substantia nigra dopamine neurons. I. Acute drug administration.
    Ostrowski NL; Caggiula AR
    J Pharmacol Exp Ther; 1991 Apr; 257(1):72-81. PubMed ID: 2020010
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The effect of 6-hydroxydopamine injections into the nucleus accumbens and substantia nigra on rat behavior].
    Saul'skaia NB
    Fiziol Zh SSSR Im I M Sechenova; 1992 Apr; 78(4):14-20. PubMed ID: 1334857
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the effects of the cholecystokinin-B receptor antagonist, PD 134308, and the cholecystokinin-A receptor antagonist, L-364,718, on dopamine neuronal activity in the substantia nigra and ventral tegmental area.
    Meltzer LT; Christoffersen CL; Serpa KA; Razmpour A
    Synapse; 1993 Feb; 13(2):117-22. PubMed ID: 8446920
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Electrophysiological effects of cholecystokinin on neurons in rat substantia nigra pars reticulata.
    Zhang J; Freeman AS
    Brain Res; 1994 Jul; 652(1):154-6. PubMed ID: 7953713
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Possible interaction between cholecystokinin and dopamine.
    Govoni S; Yang HY; Bosio A; Pasinetti G; Costa E
    Adv Biochem Psychopharmacol; 1982; 33():437-44. PubMed ID: 7124508
    [No Abstract]   [Full Text] [Related]  

  • 14. Dose-dependent feeding in the rat following substantia nigra acetylcholinesterase blockade.
    Winn P; Redgrave P
    Eur J Pharmacol; 1981 Dec; 76(4):421-5. PubMed ID: 6276195
    [No Abstract]   [Full Text] [Related]  

  • 15. Pertussis toxin blocks autoreceptor-mediated inhibition of dopaminergic neurons in rat substantia nigra.
    Innis RB; Aghajanian GK
    Brain Res; 1987 May; 411(1):139-43. PubMed ID: 2955848
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neurotensin-dopamine interactions in the substantia nigra of the rat brain.
    Merchant KM; Bush LG; Gibb JW; Hanson GR
    J Pharmacol Exp Ther; 1990 Nov; 255(2):775-80. PubMed ID: 2147039
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dopaminergic receptor activity in substantia nigra in the mechanisms of autoregulation of striatal dopamine release.
    Groppetti A; Parenti M; Cattabeni F; Maggi A; De Angelis L; Monduzzi M; Racagni G
    Adv Biochem Psychopharmacol; 1978; 19():363-71. PubMed ID: 696464
    [No Abstract]   [Full Text] [Related]  

  • 18. Differential effects of D1 and D2 dopamine receptor agonists on substantia nigra pars reticulata neurons.
    Waszczak BL
    Brain Res; 1990 Apr; 513(1):125-35. PubMed ID: 2140951
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of cholecystokinin-like peptides in schizophrenics and normal human subjects.
    Hommer DW; Pickar D; Crawley JN; Weingartner H; Paul SM
    Ann N Y Acad Sci; 1985; 448():542-52. PubMed ID: 3896099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Intracerebroventricular administration of cholecystokinin inhibits the dopamine- and serotoninergic systems of the brain].
    Vasar EE; Otter MIa; Riago LK
    Fiziol Zh SSSR Im I M Sechenova; 1982 Sep; 68(9):1218-22. PubMed ID: 7173435
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.